medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 3

<< Back Next >>

Ann Hepatol 2013; 12 (3)

Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy

do Espírito-Santo MP, Brandão-Mello CE, Alves MV, Lampe E, De Almeida AJ

Language: English
References: 32
Page: 373-379
PDF size: 103.73 Kb.


ABSTRACT

Introduction. Detection of hepatitis C virus (HCV) has been reported in extrahepatic sites such as peripheral blood mononuclear cells and platelets. Quantitation of HCV-RNA in platelets from patients under antiviral therapy has not been reported. Material and methods. HCV-RNA levels in paired serum and platelet samples of 17 chronically HCV-infected patients were determined at baseline, week 12, end-of-treatment, and 24 weeks after completion of treatment with pegylated interferon plus ribavirin. Quantitation of HCVRNA load was performed using COBAS® TaqMan® HCV Test v 2.0 (lower limit of detection, 25 IU/mL). The cohort predominantly consisted of female (59%) with a mean age of 50.7 ± 10.0 years. Results. Measurements of HCV-RNA in relation to different timepoints of therapy revealed baseline viral load was most frequently detected in higher levels in serum than in platelets (5.6 x 104 IU/mL vs. 379.0 IU/mL; p = 0.0002), a trend also demonstrated in most samples throughout the study. HCV-RNA was also found at low levels (‹ 25.0-314.0 UI/mL) persistently in platelets of three patients who have lost detectable HCV-RNA in serum during antiviral therapy, resulting in virological relapse. Conclusion. HCV-RNA levels are most frequently detected in higher levels in serum than in platelets, independent of timepoint of antiviral therapy. Further studies with an increase in size of the samples are needed to better evaluate whether or not patients who presented HCV-RNA at low levels in platelets after having lost detectable HCV-RNA in serum during antiviral therapy are at increased risk of relapse of HCV infection during follow-up evaluation.


REFERENCES

  1. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005; 17: 447-55.

  2. De Almeida AJ, Campos-de-Magalhães M, Brandão-Mello CE, de Oliveira RV, Yoshida CF, Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to host and viral factors. Hepatogastroenterology 2007; 54: 964-8.

  3. De Almeida AJ, Campos-de-Magalhães M, de Melo Marçal OP, Brandão-Mello CE, Okawa MY, de Oliveira RV, do Espírito- Santo MP, et al. Hepatitis C virus-associated thrombocytopenia: a controlled prospective, virological study. Ann Hematol 2004; 83: 434-40.

  4. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 2001; 98: 2293-300.

  5. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 135-40.

  6. Alter HJ. An unexpected link between HCV and platelets. Blood 2001; 98: 2291.

  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

  8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  9. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006; 194: 53-60.

  10. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez- Iñigo E, de Lucas S, Salas C et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.

  11. Mohamad HI, El-Bab HK, Kamal AM. HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy. Hepatogastroenterology 2011; 58: 932-6.

  12. De Almeida AJ, Campos-de-Magalhães M, Brandão-Mello CE, de Oliveira RV, do Espirito-Santo MP, Yoshida CF, Lampe E. Detection of hepatitis C virus in platelets: evaluating its relationship to antiviral therapy outcome. Hepatogastroenterology 2009; 56: 429-36.

  13. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.

  14. Colucci G, Ferguson J, Harkleroad C, Lee S, Romo D, Soviero S, Thompson J, et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007; 45: 3595-600.

  15. Otto TD, Vasconcellos EA, Gomes LH, Moreira AS, Degrave WM, Mendonça-Lima L, Alves-Ferreira M. ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility. Genet Mol Res 2008; 7: 861-71.

  16. Bedossa P, Poynard T. The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.

  17. Revie D, Salahuddin SZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J 2011; 8: 346.

  18. Torres B, Martin JL, Caballero A, Villalobos M, Olea N. HCV in serum, peripheral blood mononuclear cells and lymphocyte subpopulations in C-hepatitis patients. Hepatol Res 2000; 18: 141-51.

  19. Trimoulet P, Bernard PH, de Ledinghen V, Oui B, Chene G, Saint-Marc Girardin MF, Dantin S, et al. Quantitation of hepatitis C virus RNA in plasma and peripheral blood mononuclear cells of patients with chronic hepatitis treated with interferon alpha. Dig Dis Sci 2000; 45: 175-81.

  20. Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/ HCV-coinfection. J Med Virol 2012; 84: 431-7.

  21. Dahari H, Forns X, Neumann AU, Perelson AS. The extrahepatic contribution to HCV plasma viremia. J Hepatol 2006; 45: 626-7.

  22. Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010; 99: 112-22.

  23. Schwertz H, Rowley JW, Tolley ND, Campbell RA, Weyrich AS. Assessing protein synthesis by platelets. Methods Mol Biol 2012; 788: 141-53.

  24. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009; 7: 241-6.

  25. Agnello V, Ábel G, Knight GB, Monteverde A, Ballare M, Bertoncelli MC, Pileri SA. Detection of hepatitis C virus (HCV) in liver, bone marrow, and lymph nodes in type II mixed cryoglobulinemia (MC) using in situ hybridization [abstract C163]. Fifth International Symposium on Hepatitis C Virus and Related Viruses; 1995 Aug. 28-Sept. 3; Gold Coast, Australia.

  26. Bordin G, Ballaré M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, Brambilla M, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995; 13: S39-S43.

  27. Li X, Jeffers LJ, Garon C, Fischer ER, Scheffel J, Moore B, Reddy KR et al. Persistence of hepatitis C virus in a human megakaryoblastic leukaemia cell line. J Viral Hepat 1999; 6: 107-14.

  28. Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ, Rodriguez I, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis 2005; 192: 258-65.

  29. Minosse C, Calcaterra S, Abbate I, Selleri M, Zaniratti MS, Capobianchi MR. Possible compartmentalization of hepatitis C viral replication in the genital tract of HIV-1-coinfected women. J Infect Dis 2006; 194: 1529-36.

  30. Blackard JT, Ma G, Welge JA, Martin CM, Sherman KE, Taylor LE, Mayer KH, et al. Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization. J Med Virol 2012; 84: 242-52.

  31. Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, et al. Lymphotropic hepatitis C virus has an interferon-resistant phenotype. J Viral Hepat 2012; 19: 254-62.

  32. Espírito-Santo MP, de Almeida AJ, Lampe E. Detection and analysis of hepatitis C virus (HCV) quasispecies in platelets from antiviral therapy-naïve patients with chronic HCV infection. Virus Rev Res 2011; 16: 187-8.




2020     |     www.medigraphic.com